aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Frontera Therapeutics, founded with a mission to revolutionize gene therapy, focuses on developing high-quality, affordable recombinant adeno-associated virus (rAAV) therapies for the global market. The company leverages its innovative APEX Technology & Manufacturing Platform, which includes novel and clinically validated AAV vectors, to address various disease areas. Frontera aims to make life-changing therapeutics accessible and scalable, ensuring that advanced medical treatments reach a broader population.
Notable figures affiliated with Frontera Therapeutics include key scientists and industry leaders in gene therapy. The company has garnered attention from significant investors in the biotechnology sector, bolstering its research and development efforts. Frontera's achievements include advancing several promising therapies into clinical stages, demonstrating the efficacy and potential of their AAV gene expression system. Overall, Frontera Therapeutics is making a substantial impact on global health by striving to provide cost-effective and high-quality gene therapy solutions.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Gene Therapy
Technology
Biotech
Tags
Therapeutics
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was Frontera Therapeutics founded?
Frontera Therapeutics was founded in 2019.
Where is Frontera Therapeutics's headquarters located?
Frontera Therapeutics's headquarters is located in Bedford, MA, US.
When was Frontera Therapeutics's last funding round?
Frontera Therapeutics's most recent funding round was for $160M (USD) in June 2022.
How many employees does Frontera Therapeutics have?
Frontera Therapeutics has 175 employees as of Feb 4, 2024.
How much has Frontera Therapeutics raised to-date?
As of July 05, 2023, Frontera Therapeutics has raised a total of $160M (USD) since Jun 24, 2022.
Add Comparison
Total Raised to Date
$160M
USD
Last Update Jun 24, 2022
Last Deal Details
$160M
USD
Jun 24, 2022
Series B
Total Employees Over Time
175
As of Feb 2024
Frontera Therapeutics Address
Bedford,
Massachusetts
01730
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts